CY1121687T1 - Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων - Google Patents

Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων

Info

Publication number
CY1121687T1
CY1121687T1 CY20191100039T CY191100039T CY1121687T1 CY 1121687 T1 CY1121687 T1 CY 1121687T1 CY 20191100039 T CY20191100039 T CY 20191100039T CY 191100039 T CY191100039 T CY 191100039T CY 1121687 T1 CY1121687 T1 CY 1121687T1
Authority
CY
Cyprus
Prior art keywords
amino acid
acid sequences
ioy
therapeutic treatment
viral diseases
Prior art date
Application number
CY20191100039T
Other languages
English (en)
Inventor
Anna Hultberg
Bram Maassen
Peter Vanlandschoot
Erik Depla
Catelijne Stortelers
Cornelis Theodorus Verrips
Steven Van Gucht
Jose Melero
Michael John Scott Saunders
Johannes Joseph Wilhelmus De Haard
Robert Anthony Weiss
Nigel James Temperton
Xavier Saelens
Bert Schepens
Alexander Szyroki
Michael Marie Harmsen
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of CY1121687T1 publication Critical patent/CY1121687T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται εν μέρει με αλληλουχίες αμινοξέων που κατευθύνονται κατά και/ή που μπορούν να δεσμευτούν ειδικά με μια πρωτεΐνη φακέλου ενός ιού, καθώς και με ενώσεις ή κατασκευάσματα, και συγκεκριμένα με πρωτεΐνες και πολυπεπτίδια που περιλαμβάνουν ή ουσιαστικά αποτελούνται από μία ή περισσότερες τέτοιες αλληλουχίες αμινοξέων.
CY20191100039T 2008-06-05 2019-01-15 Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων CY1121687T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5905508P 2008-06-05 2008-06-05
US9299108P 2008-08-29 2008-08-29
US13913008P 2008-12-19 2008-12-19
US14465309P 2009-01-14 2009-01-14
US17291409P 2009-04-27 2009-04-27
US17410809P 2009-04-30 2009-04-30
PCT/EP2009/056975 WO2009147248A2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Publications (1)

Publication Number Publication Date
CY1121687T1 true CY1121687T1 (el) 2020-07-31

Family

ID=41055279

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100039T CY1121687T1 (el) 2008-06-05 2019-01-15 Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων

Country Status (17)

Country Link
US (4) US9193780B2 (el)
EP (2) EP2285408B1 (el)
JP (2) JP5809557B2 (el)
CN (1) CN102112155B (el)
AU (1) AU2009254501B2 (el)
CA (1) CA2726652A1 (el)
CY (1) CY1121687T1 (el)
DK (1) DK2285408T3 (el)
ES (1) ES2713864T3 (el)
HR (1) HRP20182195T1 (el)
HU (1) HUE042053T2 (el)
LT (1) LT2285408T (el)
PL (1) PL2285408T3 (el)
PT (1) PT2285408T (el)
SI (1) SI2285408T1 (el)
WO (1) WO2009147248A2 (el)
ZA (1) ZA201009135B (el)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CA2746395C (en) 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
AU2015200057B9 (en) * 2009-06-05 2017-03-09 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) Nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US20120195900A1 (en) * 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP3466972A1 (en) 2011-06-23 2019-04-10 Ablynx NV Serum albumin binding proteins
CN104114186B (zh) * 2011-08-03 2017-05-03 儿童医疗中心有限公司 识别流行性感冒血凝素的受体‑结合袋状结构的广泛中和人类抗体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
HUE044263T2 (hu) * 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
LT2970449T (lt) * 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
MX2015013901A (es) * 2013-04-05 2015-12-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
EP3035970A1 (en) * 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
EP3074423A1 (en) * 2013-11-25 2016-10-05 Oxford BioTherapeutics Ltd Antibodies anti matriptase for the treatment of cancer
SG11201702688UA (en) * 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
AU2016209247B2 (en) 2015-01-21 2021-02-25 Inhibrx Biosciences, Inc. Non-immunogenic single domain antibodies
SG11201705614QA (en) 2015-02-05 2017-08-30 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
WO2016150845A1 (en) * 2015-03-20 2016-09-29 Ablynx Nv Glycosylated immunoglobulin single variable domains
WO2016156475A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
IL254577B2 (en) 2015-03-31 2023-11-01 Vhsquared Ltd polypeptides
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3124042A1 (en) 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3313432A1 (en) 2015-06-18 2018-05-02 VIB vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
PL3322734T3 (pl) * 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
JP2017036258A (ja) * 2015-08-07 2017-02-16 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
CA2997181A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP7189211B2 (ja) 2017-10-11 2022-12-13 ナンジン レジェンド バイオテック カンパニー，リミテッド 血清中のタンパク質の半減期を増加させるための組成物及び方法
PT3694529T (pt) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Proteínas triespecíficas e métodos de utilização
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
BR112020021652A2 (pt) * 2018-04-23 2021-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vetores quiméricos
CN108794626B (zh) * 2018-06-18 2021-10-12 上海大学 一种多肽以及能靶向HIV包膜蛋白gp120的金纳米抗体
CN108640978A (zh) * 2018-06-20 2018-10-12 上海大学 特异性结合HIV病毒上蛋白gp120的多肽及其应用
US11773155B2 (en) 2018-08-09 2023-10-03 Beijing Wisdomab Biotechnology Co., Ltd Bispecific antibody against rabies virus, and application thereof
JP7190675B2 (ja) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
JP7190674B2 (ja) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN112888455A (zh) * 2018-10-25 2021-06-01 Km生物医薬股份公司 修饰CMVgB蛋白及包含其的CMV疫苗
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
CN111393512B (zh) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用
WO2021216537A1 (en) * 2020-04-20 2021-10-28 Ab Studio Inc. Anti-coronavirus antibodies and uses thereof
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
WO2022006219A2 (en) 2020-07-02 2022-01-06 Trustees Of Tufts College Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
CN116171384A (zh) * 2020-08-19 2023-05-26 匹兹堡大学 联邦高等教育系统 冠状病毒纳米抗体及其使用和鉴定方法
CN116829186A (zh) * 2020-11-16 2023-09-29 Ab诊疗公司 多特异性抗体及其用途
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
CN113234151B (zh) * 2021-06-08 2022-02-15 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于靶向SARS-CoV2病毒S蛋白的三聚体纳米抗体的CAR-NK的研制
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof
WO2024068744A1 (en) * 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
CN116375852B (zh) * 2023-03-10 2024-02-02 华南农业大学 重组荧光纳米抗体及其在制备狂犬病病毒检测试剂中的应用
CN117720648A (zh) * 2023-06-13 2024-03-19 康元医疗科技(大连)有限公司 一种纳米抗体、包含该纳米抗体的多肽及其应用
CN116987194B (zh) * 2023-09-26 2023-12-26 江西乐成欣生生物技术研究有限责任公司 人st2抗原的模拟表位肽的抗独特型纳米抗体及应用
CN117683137B (zh) * 2023-12-04 2024-09-17 江苏省农业科学院 靶向新城疫病毒和h9亚型禽流感病毒的重组双特异性纳米抗体及其制备方法和应用
CN117843801B (zh) * 2023-12-29 2024-08-02 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
CA2270288A1 (en) 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
OA11862A (en) * 1999-04-22 2006-03-02 Unilever Nv Inhibition of viral infection using monovalent antigen-binding proteins.
US6133571A (en) * 1999-04-26 2000-10-17 Lockheed Martin Corporation Resonant cavity field enhancing boundary
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CO5280147A1 (es) 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP2005516939A (ja) 2001-12-18 2005-06-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断及び治療用途の精製ｃ型肝炎ウイルス外被タンパク質
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP2395016A3 (en) * 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
DK1737971T3 (da) * 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
US20050288491A1 (en) * 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20060115485A1 (en) 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
JP5011277B2 (ja) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
AU2006234847A1 (en) * 2005-04-08 2006-10-19 Medimmune, Llc Antibodies against mammalian metapneumovirus
CA2649009A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
AU2007310838A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
EP2097451A2 (en) 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP2096121A1 (en) 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
AU2009254501B2 (en) * 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
MX340541B (es) * 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Also Published As

Publication number Publication date
AU2009254501B2 (en) 2014-07-31
CN102112155A (zh) 2011-06-29
US11518799B2 (en) 2022-12-06
LT2285408T (lt) 2019-01-25
US20110182897A1 (en) 2011-07-28
EP2285408A2 (en) 2011-02-23
JP2011521662A (ja) 2011-07-28
US20200123233A1 (en) 2020-04-23
US10550174B2 (en) 2020-02-04
ES2713864T3 (es) 2019-05-24
PT2285408T (pt) 2019-02-01
EP3424526A1 (en) 2019-01-09
US9834595B2 (en) 2017-12-05
CA2726652A1 (en) 2009-12-10
HRP20182195T1 (hr) 2019-02-22
EP2285408B1 (en) 2018-10-24
CN102112155B (zh) 2016-08-10
US9193780B2 (en) 2015-11-24
AU2009254501A1 (en) 2009-12-10
JP2015156867A (ja) 2015-09-03
JP5809557B2 (ja) 2015-11-11
US20190077847A1 (en) 2019-03-14
US20160152693A1 (en) 2016-06-02
ZA201009135B (en) 2012-06-27
WO2009147248A3 (en) 2010-07-15
SI2285408T1 (sl) 2019-02-28
HUE042053T2 (hu) 2019-06-28
DK2285408T3 (en) 2019-02-04
PL2285408T3 (pl) 2019-05-31
WO2009147248A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1119233T1 (el) Προϊοντα γονιδιων εκφραζομενα διαφορικα μεσα σε ογκους και εφαρμογη αυτων
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1126300T1 (el) Bcma (cd269/tnfrsf17) - πρωτεϊνες δεσμευσης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CY1118994T1 (el) Πρωτεϊνες συνδεσης αντιγονου il-17 υποδοχεα α
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
CY1117786T1 (el) Διαφορικα εκφραζομενα σε ογκους γονιδιακα προϊοντα και χρηση αυτων
CY1116011T1 (el) Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CO6470802A2 (es) Péptido auxiliar del antígeno del cáncer
CY1116482T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης
EA201200515A1 (ru) Полипептиды и их применение
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων